Technology Area: Drug Development
248 Results for 'Drug Development'
- Technologies (21)
- Collaborations (0)
- Team (0)
- News (173)
- Pages (0)
- Multimedia (54)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 21
-
HarborSite: Precise and Efficient Gene Editing for Next-Generation Gene Therapies
The HarborSite next-generation gene therapy platform enables integration of therapeutic genes into genomic safe harbors using highly specific and efficient recombinases to enable more predictable, safe and durable gene therapies. -
DNA Nanoswitches: “Lab-on-a-Molecule” Drug Discovery
The Lab-on-a-Molecule platform leverages the Wyss Institute’s DNA nanotechnology technology for the high-throughput, low-cost screening of a wide range of chemical and biologic compounds to enable the discovery of first-in-class therapeutics for various conditions. -
Pancreatitis Tx: An Engineered Protein Treatment for Pancreatitis
First disease-modifying therapy that can be systemically applied to safely and effectively treat patients with different forms of pancreatitis. -
Sparkle: Instant Biosensors for Real-Time Imaging
Sparkle is revolutionizing the binder assay industry by harnessing novel chemistry to create instant fluorescent biosensors for a wide variety of uses. -
CogniXense for Rare Disease Drug Discovery
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome. -
SPEAR: Ultrasensitive Protein Detection in Small Samples
Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized.
News 173
Multimedia 54
-
Video/AnimationReimagining Recovery and Pain Management After Her Injury: Megan SperryMegan Sperry is a Postdoctoral Fellow working on the Biostasis project to help develop therapeutics that could slow down biological time. In this video, she shares a personal story about an injury she suffered after years of figure skating and how she would Reimagine the World with better recovery outcomes and pain management after trauma.... -
Audio/PodcastAnimal Free Labcast #4 – The PioneerWorld-class pioneer of biomedical research and innovation, Dr. Don Ingber, is the founding director of Harvard University’s Wyss Institute for Biologically Inspired Engineering. In 2010, Dr. Ingber developed a lung-on-a-chip – the first of its kind – and has continued to lead the field by developing numerous other organ chip models, demonstrating their ability to... -
Video/AnimationFrontier Science #10: Bioelectrics w/ Michael LevinMichael Levin, a Wyss Associate Faculty member and a Distinguished Professor in the Biology department at Tufts, holds the Vannevar Bush endowed Chair and serves as director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. Recent honors include the Scientist of Vision award and the Distinguished Scholar... -
Video/AnimationBeating Back the Coronavirus: FDA-Approved Drug Repurposing PipelineWith the goal of rapidly repurposing FDA-approved drugs to treat COVID-19, the Wyss Institute is collaborating with the Frieman Lab at the University of Maryland Medical School and the tenOever Lab at the Icahn School of Medicine at Mount Sinai to establish a multidisciplinary pipeline that can rapidly predict, test, and validate potential treatments. Credit:... -
Video/AnimationBeating Back the CoronavirusWhen the coronavirus pandemic forced Harvard University to ramp down almost all on-site operations, members of the Wyss Institute community refocused their teams, and formed new ones, in order to fight COVID-19 on its multiple fronts. These efforts include building new pieces of personal protective equipment that were delivered to frontline healthcare workers, developing new... -
Video/AnimationCogniXense: Speeding Up Treatments for Rare DiseasesAt the Wyss Institute, we are tackling Rett syndrome, a rare disease that affects 1 out of 9,000 children, by developing a scalable model for neurodevelopmental and cognitive diseases. This model can test drugs to see which will improve memory, learning, and behavior, with the end goal of finding effective therapies. Credit: Wyss Institute at...